Iguratimod suppresses Tfh cell differentiation in primary Sjögren’s syndrome patients through inhibiting Akt/mTOR/STAT3 signaling

Iguratimod suppresses Tfh cell differentiation in primary Sjögren’s syndrome patients through inhibiting Akt/mTOR/STAT3 signaling

Abstract Background Iguratimod (IGU) reduces hypergammaglobulinemia and disease activity in pSS (primary Sjögren’s syndrome) patients. However, the therapeutical mechanism of IGU for pSS remains largely unknown. This study aimed to investigate the regulation of Tfh cell differentiation by IGU in pSS...

Full description

Bibliographic Details
Main Authors: Taibiao Lyu, Hui Jiang, Liuting Zeng, Suying Liu, Chengmei He, Chaowen Luo, Lin Qiao, Yan Zhao, Hua Chen
Format: Article
Language:English
Published: BMC 2023-08-01
Series:Arthritis Research & Therapy
Subjects:
Primary Sjögren’s syndrome
Iguratimod
Follicular helper T cell
Online Access:https://doi.org/10.1186/s13075-023-03109-4

Internet

https://doi.org/10.1186/s13075-023-03109-4

Similar Items